Optimizing complement-activating antibody-based cancer immunotherapy: a feasible strategy?

Journal of Translational Medicine
E FonsattiM Maio

Abstract

Passive immunotherapy with monoclonal antibodies (mAb) targeted to specific tumor-associated antigens is amongst the most rapidly expanding approaches to biological therapy of cancer. However, until now a limited number of therapeutic mAb has demonstrated clinical efficacy in selected neoplasia. Results emerging from basic research point to a deeper characterization of specific biological features of neoplastic cells as crucial to optimize the clinical potential of therapeutic mAb, and to identify cancer patients who represent the best candidates to antibody-based immunotherapy. Focus on the tissue distribution and on the functional role of membrane complement-regulatory proteins such as Protectin (CD59), which under physiologic conditions protects tissues from Complement (C)-damage, might help to optimize the efficacy of immunotherapeutic strategies based on C-activating mAb.

References

Nov 1, 1986·Proceedings of the National Academy of Sciences of the United States of America·R F Irie, D L Morton
Jul 1, 1994·European Journal of Immunology·L BjørgeR Matre
Mar 24, 2004·Trends in Immunology·Kyra A GeldermanArko Gorter
May 4, 2004·The Lancet Oncology·Marion Harris

❮ Previous
Next ❯

Citations

Apr 14, 2009·Cancer Immunology, Immunotherapy : CII·Dorota Hoja-ŁukowiczAnna Lityńska
Jan 1, 2008·Journal of Oncology·Joanne M Bowen, Dorothy M K Keefe
Jul 10, 2013·International Journal of Oncology·Baijun LiZhiwei Wang

❮ Previous
Next ❯

Related Feeds

Adrenocortical Carcinoma

Adrenocortical carcinoma (ACC) is a rare malignancy of the adrenal cortex, associated with a generally dismal prognosis owing to its aggressive behavior. Here are the latest discoveries pertaining to this disease.

Antibody-Dependent Cell Cytotoxicity

Antibody-dependent cellular toxicity refers to the lysis of a target cell by a non-sensitized effector cell of the immune system as a result of antibodies binding to the target cell membrane and engaging the Fc receptors on the immune effector cells. Find the latest research on antibody-dependent cellular toxicity here.